Who owns RYTM? 13F holders and whale ownership
RYTM is tracked across public portfolios in Whale Analyzer. This page answers who owns RYTM, which top funds are buying RYTM, aggregate disclosed value, and recent position changes based on public data. Peter Kolchinsky is the largest reported holder at $580M; the top five funds control 100.0% of reported ownership; institutions were net selling last quarter (1 increased, 2 reduced); the stock trades above the aggregate whale cost basis of $15.08. Top tracked holders include Peter Kolchinsky, Baker Bros. Advisors, PRIMECAP Management, and Joseph Edelman.
Continue to the live RYTM dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Peter Kolchinsky 13F portfolio RA Capital Management holdings | $579.8M | 6.7M | Held |
| Baker Bros. Advisors 13F portfolio Baker Bros. Advisors holdings | $487.4M | 5.6M | Held |
| PRIMECAP Management 13F portfolio PRIMECAP Management Company holdings | $297.2M | 3.4M | Reduced |
| Joseph Edelman 13F portfolio Perceptive Advisors holdings | $206.4M | 2.4M | Reduced |
| Samuel Isaly 13F portfolio OrbiMed Advisors holdings | $27.3M | 314.1K | Increased |
Ownership concentration
Reported ownership of RYTM is highly concentrated across tracked institutions.
- Single largest holder: 36.3% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 5 tracked institutions, 2 held, 2 reduced, 1 increased. Net positioning is net selling.
- Peter Kolchinsky — RA Capital Management ($579.8M) (→ 0.0% qoq shares) · avg cost $21.80
- Baker Bros. Advisors — Baker Bros. Advisors ($487.4M) (→ 0.0% qoq shares) · avg cost $7.09
- PRIMECAP Management — PRIMECAP Management Company ($297.2M) (▼ 1.8% qoq shares)
- Joseph Edelman — Perceptive Advisors ($206.4M) (▼ 6.8% qoq shares)
- Samuel Isaly — OrbiMed Advisors ($27.3M) (▲ 31.0% qoq shares)
Whale cost basis vs current price
The aggregate tracked cost basis is $15.08 versus a current price of $109.84, so RYTM trades above its cost basis (+628.3%). Average unrealized P&L across tracked holders: 747%.
Sector positioning — Health Care
RYTM sits within the Health Care sector alongside 221 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live RYTM dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- ASND whale holders — ASCENDIS PHARMA A/S - ADR
- PCVX whale holders — VAXCYTE INC
- TYRA whale holders — TYRA BIOSCIENCES INC
- SION whale holders — SIONNA THERAPEUTICS INC
- EWTX whale holders — EDGEWISE THERAPEUTICS INC
- NAMSW whale holders — NEWAMSTERDAM PHARMA CO NV
- NUVL whale holders — NUVALENT INC-A
- DNTH whale holders — DIANTHUS THERAPEUTICS INC
Learn more in Whale Analyzer Academy
Deepen your read on RYTM with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns RYTM stock?
Whale Analyzer tracks 5 public institutional holders of RYTM with a combined reported value of $1.60B. See the holder table above for the largest tracked positions.
Which top funds are buying RYTM?
Tracked institutions were net selling last quarter — 2 held, 2 reduced, 1 increased. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is RYTM ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is RYTM above or below the whale cost basis?
The aggregate tracked cost basis is $15.08 versus a current price of $109.84 (+628.3%).
What does 13F ownership mean for RYTM?
Use the interactive RYTM dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.